Frovatriptan

From WikiProjectMed
Jump to navigation Jump to search
Frovatriptan
Frovatriptan structure.svg
Names
Trade namesFrova, Migard, others
Other namesFrovatriptan succinate, 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
(6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
  • (+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
Clinical data
Drug classTriptan[1]
Main usesMigraine headaches[1]
Side effectsTiredness, numberness, flushing, dry mouth, pain, heart burn, trouble sleeping[1]
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
use
By mouth
Typical dose2.5 mg[2]
External links
AHFS/Drugs.comMonograph
US NLMFrovatriptan
MedlinePlusa604013
Legal
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetics
Bioavailability20–30%
MetabolismLiver
Elimination half-life26 hours
ExcretionKidney
Chemical and physical data
FormulaC14H17N3O
Molar mass243.310 g·mol−1
3D model (JSmol)
  • CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C3
  • InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 checkY
  • Key:XPSQPHWEGNHMSK-SECBINFHSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Frovatriptan, sold under the brand name Frova among others, is a medication used to treat migraine headaches.[1] It may also be used to prevent menstrual migraine.[2] It is taken by mouth.[2]

Common side effects include tiredness, numberness, flushing, dry mouth, pain, heart burn, and trouble sleeping.[1] Other side effects may include serotonin syndrome, high blood pressure, heart attack, and medication overuse headaches.[1] Safety in pregnancy is unclear, and use within 24 hours of breastfeeding is not recommended.[3] It is a triptan.[1]

was approved for medical use in the United States in 2001.[1] It is available as a generic medication. In the United Kingdom 6 pills of 2.5 mg costs the NHS about £6 as of 2021.[2] This amount in the United States costs about 67 USD.[4]

Medical uses

Frovatriptan is used in the treatment of migraine.[5] It may also be used for short term prevention of menstrual migraine.[6]

Dosage

It is available as 2.5 mg tablets. One is recommended as soon as the headache starts, with a maximum dose of 5 mg per day.[2]

Contraindications

Frovatriptan should not be given to patients with:

  • Ischemic heart disease
  • Cerebrovascular syndrome
  • Peripheral vascular disease
  • Uncontrolled hypertension
  • Hemiplegic or basilar migraine

Side effects

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Pharmacology

Pharmacodynamics

Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.

Pharmacokinetics

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.[citation needed]

Society and culture

The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[7]

Licensing

Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.[8]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Frovatriptan Monograph for Professionals". Drugs.com. Retrieved 12 December 2021.
  2. 2.0 2.1 2.2 2.3 2.4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 500. ISBN 978-0857114105.
  3. "Frovatriptan (Frova) Use During Pregnancy". Drugs.com. Retrieved 12 December 2021.
  4. "Frovatriptan Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 12 December 2021.
  5. Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.
  6. MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.
  7. "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
  8. "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.

External links

Identifiers: